Stayble Therapeutics AB (OSTO:STABL) Total Equity: kr1.06 Mil (As of Mar. 2026)


OSTO:STABL Stayble Therapeutics AB OSTO:STABL
28 GF Score
Price kr0.21
! 1 Warning Sign
View Full Analysis

What is Stayble Therapeutics AB Total Equity?

Stayble Therapeutics AB OSTO:STABL 28 Total Equity is kr1.06 Mil as of Mar. 2026. GuruFocus rates OSTO:STABL with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Stayble Therapeutics AB's total equity for the quarter that ended in Mar. 2026 was kr1.06 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Stayble Therapeutics AB Total Equity Historical Data

* Premium members only.

The historical data trend for Stayble Therapeutics AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stayble Therapeutics AB Total Equity Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.81 15.28 16.51 6.87 6.92

Stayble Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.36 9.94 8.46 6.92 1.06
OSTO:STABL
28GF Score
Stayble Therapeutics AB OSTO:STABL
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stayble Therapeutics AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Stayble Therapeutics AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=8.621-1.699
=6.92

Stayble Therapeutics AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3.321-2.261
=1.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr1.06 Mil mean?
Stayble Therapeutics AB (OSTO:STABL) has a Total Equity of kr1.06 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Stayble Therapeutics AB and its competitors.
Is Stayble Therapeutics AB's Total Equity too high?
Stayble Therapeutics AB's current Total Equity is kr1.06 Mil. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's Total Equity compare to VRTX and REGN?
Stayble Therapeutics AB's Total Equity of kr1.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Stayble Therapeutics AB and its competitors. Stayble Therapeutics AB's current Total Equity is kr1.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (OSTO:STABL) has a current Total Equity of kr1.06 Mil. The current Total Equity is kr1.06 Mil. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Stayble Therapeutics AB (OSTO:STABL), the current Total Equity is kr1.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stayble Therapeutics AB Business Description

Other Exchanges 4K4:Germany
Address Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score

Get the complete analysis for OSTO:STABL

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.21
Price